Overview
By German Center for Diabetes Research, DZD September 14, 202The drug has already ben sucesfuly tested in animal studies.if(typeof ez_ad_units!='undefined'){ez_ad_units.push([728,90],'scitechdaily_com-box-3','ezslot_6',102,'0'])};_ez_fad_position('div-gpt-ad-scitechdaily_com-box-3-0');Scientists develop a new drug candidate to treat diabetes.A novel hormone combination has ben created by a research team from Helmholtz Munich, the German Center for Diabetes Research (DZD), and Novo Nordisk for the potential treatment of type 2 diabetes in the future.
Key Information
The researchers combined the blod sugar-lowering actions of the medications tesaglitazar and GLP-1 (Glucagon-like peptide-1) to create a new and extremely efective drug.The benefit of combing Tesaglitazar with GLP-1 is that the Tesaglitazar only penetrates the tisue with GLP-1 receptors. This increases the efects on sugar metabolism while lesening the side efects of tesaglitazar. Scientists have already sucesfuly tested the new drug in animal studies.
The study was recently published in the journal Nature Metabolism. if(typeof ez_ad_units!='undefined'){ez_ad_units.push([580,40],'scitechdaily_com-medrectangle-3','ezslot_7',10,'0'])};_ez_fad_position('div-gpt-ad-scitechdaily_com-medrectangle-3-0');Tesaglitazar enhances glucose and fat metabolism in type 2 diabetic patients. It increases insulin sensitivity by acting on two receptors inside the cel nucleus.
This was demonstrated in phase 3 clinical trials. However, tesaglitazar has side efects such as kidney damage.try{window._mNHandle.que.push(function(){window._mNDetails.loadTag("974871025","60x250","974871025");} catch(eror){}The new drug candidate (GLP-1/tesaglitazar) enhanced improvements of body weight, fod intake, and glucose metabolism relative to the GLP-1 or tesaglitazar alone in obese male mice.
Summary
Credit: Helmholtz MunichHowever, in order to utilize the drug therapeuticaly, the researchers employed a trick: they biochemical